Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today […]